July 2017
MoTuWeThFrSaSu 
     1226
345678927
1011121314151628
1718192021222329
2425262728293030
31      31
Lipid Club Newsletter Archive

Archive

2013
2012
2010
2009
2008
2007
2006
2005

 

Archive 2015

March 2015 :
  • De IMPROVE-IT Studie: voordeel van het toevoegen van ezetimibe aan simvastatine om cardiovasculaire ziekten te voorkomen.
  • Étude improve-it: Bénéfice de l’ajout d’ézétimibe à une statine pour prévenir les maladies cardiovasculaires

Vieuw

↑  Top archive

 

Archive 2014

October 2014 :
  • Tableau SCORE adapté pour le HDL-cholestérol Une mise à jour
  • Au sujet de l’étude enhance : interprétations et implications thérapeutiques
  • Atherosclerosis
  • Mettons en pratique le traitement des dyslipidémies selon les nouvelles Recommendations européennes
  • Les nouvelles Recommendations européennes pour le traitement des dyslipidémies en prévention cardiovasculaire
  • Nieuwe europese richtlijnen voor de behandeling van dyslipidemie in het kader van cardiovasculaire preventie
  • Comment je traite ... une dyslipidémie en fonction du profil de risque cardiovasculaire
  • Les Nouvelllles Recommendations européennes pour le traitement des dyslipidémies en prévention cardiovasculaire
  • Qu’apportent les nouvelles Recommendations américaines à propos de la prise en charge des dyslipidémies en prévention Cardiovasculaire ? Comparaison avec les Recommendations européennes et belges

Vieuw

↑  Top archive

 

Archive 2013

March 2013 :

  • Kidney and cardiovascular diseases: Myeloperoxidase activity and its products during hemodialysis.
  • Guidelines on CVD prevention: Confusing or complementary?
  • Does diet-beverage intake affect dietary consumption patterns? Results from the Choose Healthy Options Consciously Everyday (CHOICE) randomized clinical trial
  • Why are the results in HPS2-THRIVE disappointing?
  • High-density Lipoprotein–based Therapy Reduces the Hemorrhagic Complications Associated With Tissue Plasminogen Activator Treatment in Experimental Stroke
  • Unrestricted Mediterranean diets beat low-fat advice for primary CVD prevention: PREDIMED
  • Atherosclerosis evident in four ancient populations, including hunter-gatherers

Vieuw

↑  Top archive

 

February 2013 :
  • Weight-loss myths
  • Lp(a) gene variant associated with aortic stenosis
  • Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study.
  • Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
  • Television Viewing and Low Leisure-Time Physical Activity in Adolescence Independently Predict the Metabolic Syndrome in Mid-Adulthood

Vieuw

↑  Top archive

 

January 2013 :
  • HPS-2 THRIVE misses primary end point: No benefit of niacin/laropiprant
  • dal-OUTCOMES: why the CETP inhibitor failed to reduce outcomes?
  • Lomitapide approved for homozygous familial hypercholesterolemia
  • Antisense oligonucleotides (Mipomersen)
  • Statins: Diabetes risk outweighed by CV benefit
  • Lipid profiles: Fasting not necessary…
  • CSL-112( ApoA1 formulation) increases cholesterol efflux in humans
  • Two new PCSK9 MAbs for LDL-lowering in phase 2
  • Wider fibrate use in mild to moderate CKD?

Vieuw

↑  Top archive

 

Archive 2013

September 2013 :
    The new EAS Consensus position on Familial Hypercholesterolemia is just published!
  • Link to the article on www.eas-society.org
  • Download the article
  • Link to the abstract article on oxfordjournals.org
  • Download the slides
  • Reports from the 81st EAS Congress, Lyon ,June 2-5, 2013
    With the help of the Highlights from the EAS and of the site:

  • Arterial pathophysiology.
  • The promise of the microRNAs?
  • Predicting or preventing plaque rupture.
  • PREDIMED
  • What is the role of functional foods?
  • Statins in metabolic syndrome: does CAPITAIN offer new insights?
  • New Drugs to improve management of the high-risk patient.
  • PCSK9 attracted much attention at EAS Lyon.
  • Familial LCAT deficiency.
  • HDL: what is the message from trials?
  • Therapies under investigation( with results soon).
  • Lp(a) and diabetes
  • Suggested articles from the 81st EAS Congress.

Vieuw

↑  Top archive

 

March 2013 :
  • Kidney and cardiovascular diseases: Myeloperoxidase activity and its products during hemodialysis.
  • Guidelines on CVD prevention: Confusing or complementary?
  • Does diet-beverage intake affect dietary consumption patterns? Results from the Choose Healthy Options Consciously Everyday (CHOICE) randomized clinical trial
  • Why are the results in HPS2-THRIVE disappointing?
  • High-density Lipoprotein–based Therapy Reduces the Hemorrhagic Complications Associated With Tissue Plasminogen Activator Treatment in Experimental Stroke
  • Unrestricted Mediterranean diets beat low-fat advice for primary CVD prevention: PREDIMED
  • Atherosclerosis evident in four ancient populations, including hunter-gatherers

Vieuw

↑  Top archive

 

February 2013 :
  • Weight-loss myths
  • Lp(a) gene variant associated with aortic stenosis
  • Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study.
  • Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
  • Television Viewing and Low Leisure-Time Physical Activity in Adolescence Independently Predict the Metabolic Syndrome in Mid-Adulthood

Vieuw

↑  Top archive

 

January 2013 :
  • HPS-2 THRIVE misses primary end point: No benefit of niacin/laropiprant
  • dal-OUTCOMES: why the CETP inhibitor failed to reduce outcomes?
  • Lomitapide approved for homozygous familial hypercholesterolemia
  • Antisense oligonucleotides (Mipomersen)
  • Statins: Diabetes risk outweighed by CV benefit
  • Lipid profiles: Fasting not necessary…
  • CSL-112( ApoA1 formulation) increases cholesterol efflux in humans
  • Two new PCSK9 MAbs for LDL-lowering in phase 2
  • Wider fibrate use in mild to moderate CKD?

Vieuw

↑  Top archive

 

Archive 2012

January 2012 :
Inhibition of PCSK9 - (proprotein convertase subtilisin/kexin type 9) : an exciting therapeutic development.
Vieuw
↑  Top archive

 

Archive 2010

January - February - Mars 2010 :
  • HDL cholesterol = an essential target
  • Largest-ever meta-analysis finds CRP is unlikely to be a causal factor for CVD
  • Lovastatin is present in certain types of red yeast rice
  • 6th Lipid & Atherosclerosis Symposium
  • The 7th International Human Peroxidase Meeting
Download Volume 22 - 1
 
April - May - June 2010 :
  • ACCORD: Fenofibrate adds no benefit to statin therapy in high-risk diabetic patients, but has a clear effect in dyslipidemic patients
  • New hypolipidemic drugs
  • More evidence of the benefit of light drinking
  • Aspirin in a new primary-prevention meta-analysis: who will benefit?
  • 6th Lipid & Atherosclerosis Symposium
  • The 7th International Human Peroxidase Meeting

Download Volume 22 - 2

August - September 2010 :
  • Vitamin D and cardiovascular diseases: Where do we stand in 2010?
  • New data about lipoprotein (a): A curious molecule or a casual cardiovascular risk factor?
  • Fibrates show “moderate” reduction in cardiac events in meta-analysis
  • 6th Lipid & Atherosclerosis Symposium
Download Volume 22 - 3
 
↑  Top archive

 

Archive 2009

January - February - Mars 2009 :
  • Effects of lysophosphatidic acid on gene expression in cultured human EAhy926 endothelial cells - Overexpression of 3 proteins involved in monocyte transmigration : IL-8, MCP-1 and pentraxin-3
  • AHA meeting report. JUPITER trial
  • N-3 fatty acid recommendations and cardiovascular benefits
Download Volume 21 - 1
 
April -May - June 2009 :
  • The “Lipido-genomic dialogue” between the mother and her child via the placenta before birth
  • Stop atherosclerosis in native diabetics study (SANDS)
  • Changes in lipoprotein composition and function induced by different revascularization procedures
Download Volume 21 - 2
July - August - September 2009 :
  • New Data on Lp(a)
  • Statins in primary prevention
  • Mediterranean diet and longevity : what is important ?
  • Inflammatory markers in the management of the metabolic syndrome
Download Volume 21 - 3
 
October - November - December 2009 :
  • Role of macrophage survival/apoptosis on atherogenesis.
  • OxLDL and preclinical atherosclerosis: lessons from the ASKLEPIOS Study.
  • Life expectancy in relation to cardiovascular risk factors: 38 year follow-up of 19,000 men in the Whitehall study.
  • A new definition of the metabolic syndrome by IDF, NHLBI, WHF, IAS and AHA
  • Cardiovascular diseases, erectile dysfunction and myeloperoxidase
Download Volume 21 - 4
↑  Top archive

 

Archive 2008

January - February - March 2008 :
  • Reports Of The Xvith International Symposium On Drugs Affecting Lipid Metabolism (DALM)
  • Reverse Cholesterol Transport : RCT
  • H D L
  • Treatment : Old And New Drugs
Download Volume 20 - 1
 
April - May - June 2008 :
  • ORBITA AWARDS 2008 - Uncoupling protein 2 mediates temperature heterogeneity in vulnerable atherosclerotic plaque
  • Human apo A-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone-marrow-derived endothelial progenitor cells
Download Volume 20 - 2
July - August - September 2008 :
  • To flush or not to flush? Effects of laropiprant on nicotinic acid-induced flushing
  • Pleiotropic Effects of Statins and Relevance to Acute Coronary Syndromes
Download Volume 20 - 3
 
October - November - December 2008 :
  • Belgian Lipid Club - Report of HDL-cholesterol Meeting 2
  • Challenges in HDL measurement
  • Non-pharmacologic effects on HDL-cholesterol (*)
  • Raising HDL-Cholesterol. More questions than answers
  • Effect of rimonabant on the progression of atherosclerosis in patients with abdominal obesity and coronary artery disease.
Download Volume 20 - 4
↑  Top archive

 

Archive 2007

January - February - March 2007 :
  • Epidemiology and risk factors of cerebrovascular diseases
  • Carotid atherosclerosis: causes and treatment
  • Lipid and cerebrovascular disease insights from SPARCL.
  • Lipids, cognition and stroke
  • Antiplatelet agents in the prevention of stroke
Download Volume 19 - 1
 
April - May - June 2007 :
  • Cell death and phagocytosis in atherosclerosis: Implications for plaque stability
  • Hemostatic and fibrinolytic Markers in obesity and type 2 diabetes: Are they a part of the “metabolic syndrome?”
Download Volume 19 - 2
July - August - September 2007 :
  • Myeloperoxidase: a new therapeutical target for the treatment of atherosclerosis?
  • Distinction between high synthesizers and high absorbers of cholesterol in optimizing cholesterol-lowering therapy
Download Volume 19 - 3
 
October - November - December 2007 :
  • Reports of the XVIth international symposium on Drugs Affecting Lipid Metabolism (Dalm)
  • Atherosclerosis and Inflammation
  • Metabolic Syndrome
  • Imaging of Atherosclerosis
  • Treatment: New Drugs
Download Volume 19 - 4
↑  Top archive

 

Archive 2006

January - February - March 2006 :
  • Economic aspects of lipid-lowering drugs
  • Use of statins in the treatment of the metabolic syndrome
Download Volume 18 - 1
 
July - August - September 2006 :
  • 14th International Symposium on Atherosclerosis
Download Volume 18 - 3
 
October - November - December 2006 :
  • Reports of the 14th International Symposium on Atherosclerosis
  • From hypercholesterolemia to hypocholesterolemia and beyond
Download Volume 18 - 4
↑  Top archive

 

Archive 2005

January - February - March 2005 :
  • 15e internationaal symposium DALM Venetië (2e deel) - Résumés du 15ème Congrès DALM Venise (2ème partie)
  • Opleving van nicotinezuur in de behandeling van dyslipidemie - Renouveau de l’acide nicotinique dans le traitement dyslipidémies
  • Vergelijking van de criteria voor de serumlipiden - Comparaison des critères lipidiques dans les différentes définitions du syndrome métabolique
Download Volume 17 - 1 NL
Download Volume 17 - 1 FR
 
April - May - June 2005 :
  • Weight-loss associated induction of PPARalpha and PPARgamma (ORBITA Prijs)
  • Genetic test in patients with severe hypercholesterolemia(MSD Prijs) O.S.
  • Questions on familial hypercholesterolemia
  • Prijs BLC 8 - Prix BLC
Download Volume 17 - 2 NL
Download Volume 17 - 2 FR
July - August - September 2005 :
  • Dyslipidemie en diabetes
  • Verhoogt een infektie met heliobacter pylori het cardiovasculair risiko van diabetespatiënten?
Download Volume 17 - 3 NL
Download Volume 17 - 3 FR
 
October - November - December 2005 :
  • HDL in Practice
  • From hypercholesterolemia to hypocholesterolemia and beyond
Download Volume 17 - 4
↑  Top archive